Phase 3 RCT in 548 adults with relapsed or refractory follicular lymphoma: adding tafasitamab to lenalidomide and rituximab improved median PFS vs placebo (22.4 vs 13.9 months; HR 0.43). Diarrhoea was more common (38% vs 28%).
RCTn = 548
Sehn et al. Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial